3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
8
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
185
Carboplatin
133
Paclitaxel
102
Cisplatin
102
Gemcitabine
86
Pemetrexed
80
durvalumab
75
Nivolumab
66
Docetaxel
56
atezolizumab
52
Bevacizumab
50
Cyclophosphamide
49
Dexamethasone
45
Capecitabine
45
Oxaliplatin
43
130-nm albumin-bound paclitaxel
42
Rituximab
40
Fulvestrant
39
Lenalidomide
38
Fluorouracil
38
Prednisone
32
osimertinib
31
olaparib
29
Leucovorin
29
venetoclax
28
fludarabine
28
Trastuzumab
27
Doxorubicin
27
Etoposide
25
Cetuximab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
tisotumab vedotin
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled